Changes in pituitary adenoma patient presentation and outcomes during the COVID pandemic at a Pituitary Center of Excellence
Authors' conclusion
Patients that presented during the pandemic tended to be more frail, have more comorbidities, and require additional extrasellar surgical approaches. Despite changes in clinical presentation and operative management, the LOS and readmission rate remained stable during COVID, supporting the safety of this procedure during the recent pandemic.
Study context
- Population
- Patients with pituitary adenoma who had endoscopic endonasal surgery (EES), 2015–2022, at a Pituitary Center of Excellence
- Participants
- 492 patients
- Exposure
- COVID vs pre-COVID period
- Pre-COVIDn = 314reference
- COVIDn = 178
Methodological detailssingle-centre, Univariate analysis with chi-square, Fisher exact tests and t-tests
- Single-centre
- Univariate analysis with chi-square, Fisher exact tests and t-tests
Main finding
As reported in the abstract
- Risk analysis index (RAI) frailty score higher in COVID group (15 ± 10 pre-COVID vs 20 ± 9 COVID, P < 0.001)
- American Society of Anesthesiology (ASA) physical status score 3 or 4 higher in COVID group (72.0% pre-COVID vs 81.9% COVID, P = 0.02)
- More macroadenoma cases during COVID (87.6% pre-COVID vs 94.4% COVID, P = 0.02)
- More extrasellar surgical approaches during COVID (45.2% pre-COVID vs 61.2% COVID, P < 0.001)
- No significant difference in length of stay (LOS) and readmission rates between groups
Observational data: associations, not effects.
Original publication
Changes in pituitary adenoma patient presentation and outcomes during the COVID pandemic at a Pituitary Center of Excellence. Pituitary. Published 24 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →